key: cord-0964109-aixl4xx1
authors: Wang, Xinjie; Zhong, Mingtian; Liu, Yong; Ma, Peixiang; Dang, Lu; Meng, Qingzhou; Wan, Wenwei; Ma, Xiaodong; Liu, Jia; Yang, Guang; Yang, Zifeng; Huang, Xingxu; Liu, Ming
title: Rapid and Sensitive Detection of COVID-19 Using CRISPR/Cas12a-based Detection with Naked Eye Readout, CRISPR/Cas12a-NER
date: 2020-05-05
journal: Sci Bull (Beijing)
DOI: 10.1016/j.scib.2020.04.041
sha: be6b01b8b693ada3a095a2c088012a0cfa2cb065
doc_id: 964109
cord_uid: aixl4xx1

nan

The outbreak of the 2019 novel coronavirus disease (COVID-19) has had a significant impact on global health. To advance the diagnostic method of COVID-19, we developed a CRISPR/Cas12a-based assay with a naked eye readout, CRISPR/Cas12a-NER. The assay can detect as few as 10 copies of the virus gene in 45 min without a special instrument and has good consistency with the qPCR assay, providing a simple and reliable on-site diagnostic method suitable for a local hospital or community testing.

An outbreak of the novel coronavirus disease (COVID-19), which first started in Wuhan, China, spread rapidly all over the world and had caused more than 1,991,562 confirmed cases with 130,885 deaths by 16 April 2020 (World Health Organization Coronavirus disease 2019 situation reports). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection leads to the disease [1] . SARS-CoV-2, a positive-sense virus, belongs to Betacoronavirus genus lineage β and is phylogenetically closely related to bat SARS-like coronaviruses [2] .

Sensitive and rapid detection of COVID-19 is crucial in controlling the outbreak.

Currently, real-time quantitative reverse transcription-polymerase chain reaction (qPCR) assays are recommended as molecular diagnostic methods [3, 4] . However, qPCR requires an elaborate instrument and professional operation, which limits its diagnostic application.

Recently, a CRISPR/Cas-based nucleic acid detection technology was developed with the advantages of sensitivity, specificity, rapidity, and simplicity [5, 6] . To advance the on-site diagnosis of COVID-19, we introduce a CRISPR/Cas12a-based rapid detection assay.

To sensitively and rapidly detect SARS-CoV-2 nucleic acid, CRISPR/Cas12a-based detection with naked eye readout, termed CRISPR/Cas12a-NER, including the Cas12a protein, SARS-CoV-2 specific CRISPR RNAs (crRNAs) and a single-stranded DNA (ssDNA) reporter, was developed as shown in Fig. 1a . To enable on-site diagnosis, an ssDNA reporter labelled with a quenched green fluorescent molecule was introduced, which will be cleaved by Cas12a when there is nucleic acid of SARS-CoV-2 in the detection system, and the resulting green fluorescence can be seen with the naked eye under 485 nm light (Fig. 1a) .

For specific detection of the SARS-CoV-2 genome, a total of 15 crRNAs, which are predicted to distinguish single nucleotide polymorphisms (SNPs) with other SARS or SARSrelated viruses, were designed on four domains of the orf1a, orf1b, N and E genes over the Wuhan-Hu-1 strain (GenBank accession number MN908947) (Fig. 1b, Fig. S1 online) . The results showed that 14 crRNAs, except the E-crRNA1, targeting SARS-CoV-2 were validated, and all of them highly and specifically reacted with synthetic gene fragments (Fig. 1c, Fig.   S2 and S3 online). As the CRISPR/Cas12a-NER readout signal relies on the crRNAdependent targeting cleavage efficiency, which is affected by the secondary structure and spacer sequence of the crRNA [7, 8] . The crRNAmix (equal mix work crRNAs targeting at each gene, named orf1a-crRNAmix, orf1b-crRNAmix, N-crRNAmix, E-crRNAmix) mediated the strongest fluorescence signal (Fig. S4 online) and was chosen for the detection of COVID-19.

As SARS-CoV-2 is an RNA virus, reverse transcript recombinase-aided amplification (RT-RAA) was combined to obtain enough DNA for Cas12a-mediated detection. The RT-RAA will amplify the target gene fragment in 30 min at 39 ℃, followed by a CRISPR/Cas12a reaction at 37 ℃ (Fig. 1a) . Cas12a-mediated detection produces a robust signal in a 15 min reaction (Fig. 1d) , and then the assay time is fixed to 15 min. The sensitivity of the CRISPR/Cas12a-NER assay was determined by the fluorescence intensities.

The results show that among the four target genes, the E-crRNAmix for the target E gene is the most sensitive, which can clearly detect 10 copies of SARS-CoV-2 synthetic nucleic acid (Fig. 1e, Fig. S5 online) . Thus, we chose E-crRNAmix for a screening assay of SARS-CoV-2, and the remaining target genes can be used for a further confirmed diagnostic assay. with clinical diagnosis, 16 were determined to be SARS-CoV-2 positive by both CRISPR/Cas12a-NER and qPCR assays and showed 100% agreement (Fig. 1f, Fig. S6 and S7 online), with the kappa value (κ) being 1.0 (p < 0.001) (Table S3) , confirming the outstanding performance of CRISPR/Cas12a-NER.

Overall, we described CRISPR/Cas12a-NER, which provides a novel alternative for the portable, simple, sensitive, and specific detection of the COVID-19 virus, providing a simple and reliable on-site diagnostic method suitable for a local hospital or community testing.

The authors declare no competing interests. 

Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding

A new coronavirus associated with human respiratory disease in china

Molecular diagnosis of a novel coronavirus (2019-ncov) causing an outbreak of pneumonia

A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-ncov) infected pneumonia (standard version)

Nucleic acid detection with crispr-cas13a/c2c2

Crispr-cas12a target binding unleashes indiscriminate single-stranded dnase activity

Good guide, bad guide: Spacer sequence-dependent cleavage efficiency of cas12a

In vivo high-throughput profiling of crispr-cpf1 activity

His research is focused on the gene-editing tool development and application, including CRISPR-based base editing and nucleic acid detection

Liu's research focuses on CRISPR-based therapeutics and diagnostics of respiratory disease